SecuraBio
27
1
2
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
40.7%
11 terminated/withdrawn out of 27 trials
56.0%
-30.5% vs industry average
19%
5 trials in Phase 3/4
71%
10 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Role: collaborator
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Role: lead
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Role: collaborator
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Role: lead
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
Role: lead
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Role: lead
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Role: lead
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Role: lead
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
Role: lead
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
Role: lead
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Role: lead
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
Role: lead
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Role: lead
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Role: lead
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Role: collaborator
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Role: lead
IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
Role: lead
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Role: lead
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
Role: lead
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Role: lead